Composition for relieving chronic obstructive pulmonary disease and preparation method thereof

Abstract

The invention belongs to the technical field of biological medicine, and particularly relates to a composition for relieving chronic obstructive pulmonary disease and a preparation method thereof. The composition provided by the invention is prepared from the following raw materials in parts by weight: 3-5 parts of pogostemon cablin, 1-3 parts of lavender, 1-2 parts of citrus peel, 1-2 parts of spearmint and 1-2 parts of asarum. Further, the raw materials are smashed and squeezed to obtain squeezed oil, meanwhile, squeezed residues are subjected to steam distillation, ethanol extraction and other operations to obtain extracts, and the obtained squeezed oil and the extracts are combined and dehydrated to obtain the composition. Besides, in order to better realize the effect of the composition in relieving the chronic obstructive pulmonary disease, the composition is compounded with an atomized solvent to prepare an atomized liquid preparation, and the obtained atomized liquid preparation shows a good improvement effect on the chronic obstructive pulmonary disease.

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to a composition for alleviating chronic obstructive pulmonary disease and a preparation method thereof. Background Art

[0002] Chronic obstructive pulmonary disease, abbreviated as COPD, is a common respiratory disease with a high incidence rate worldwide. Its main feature is that the lungs are affected by continuous airflow obstruction, which can cause chronic lung inflammation, excessive mucus secretion, airway remodeling, emphysema and many other problems, resulting in more serious lung diseases, with high disability and mortality rates. At present, the disease has become the third leading cause of death in the world, but it is also a preventable and remedial disease.

[0003] At present, oral chemical drugs are mostly used to alleviate and improve chronic obstructive pulmonary disease. Oral administration is simple and does not directly damage the skin or mucous membranes. It is painless and non-invasive. However, oral drugs are slow to take effect during the absorption process, and the efficacy is easily affected by gastrointestinal function and gastrointestinal contents. The bioavailability of drugs is low, and long-term use may also cause drug resistance. Therefore, the long-term treatment effect of oral drug treatment is not ideal.

[0004] In order to solve the drawbacks of oral drugs, existing research has begun to make drugs for relieving chronic obstructive pulmonary disease into a form of spray, aerosol or nasal drops, etc., and deliver the drugs to the body through nasal administration. For example, patent CN113694100A discloses a spray medicine for relieving chronic obstructive pulmonary disease. However, the patent uses supercritical carbon dioxide extraction technology to obtain volatile oil components of various raw materials, and the cost of industrial production is very high and the economic benefit is poor. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a composition for alleviating chronic obstructive pulmonary disease and a preparation method thereof.

[0006] The first aspect of the present invention is to provide a composition for alleviating chronic obstructive pulmonary disease, wherein the composition is prepared from the following raw materials in parts by weight: 3-5 parts of patchouli, 1-3 parts of lavender, 1-2 parts of citrus peel, 1-2 parts of spearmint, and 1-2 parts of asarum.

[0007] Preferably, 4 parts of patchouli, 2 parts of lavender, 2 parts of citrus peel, 1 part of spearmint, and 1 part of asarum.

[0008] As further preferred, the patchouli is patchouli leaves, the lavender is lavender flowers, the citrus peel is the dried ripe citrus peel, the spearmint is the stems and leaves of spearmint, and the asarum is the roots and stems of asarum.

[0009] Patchouli is recorded in the Chinese Pharmacopoeia as "spicy and warm in nature, and enters the spleen, stomach, and lung meridians. It has the effects of aromatic turbidity, soothing the stomach and stopping vomiting, and relieving heat." Patchouli leaves are rich in patchouli volatile oil, mainly containing active ingredients such as patchoulene, patchouli alcohol, and patchouli ketone. It has good effects on dampness and turbidity blocking the middle, abdominal distension and vomiting, the initial onset of dampness and heat, fever and fatigue, chest tightness, cold and dampness, abdominal pain, vomiting and diarrhea, and sinusitis and headache.

[0010] Lavender is pungent and cool in nature. Studies have shown that lavender essential oil extracted from lavender is rich in more than 30 different types of aromatic compounds, the main components of which include linalool, linalyl acetate, eucalyptol, B-rosinene, lavandin acetate, lavandinol, terpene-4-ol, camphor, etc. "Chinese Materia Medica" records that lavender has the effects of clearing away heat and detoxifying, dispersing wind and relieving itching.

[0011] Citrus peel, also known as tangerine peel, noble old peel, and red peel, is bitter and warm in nature, and enters the spleen and lung meridians. In addition to cellulose, lignin, essential oils and other ingredients, citrus peel also contains a lot of pectin, flavonoids, and polyphenol compounds, which have the effects of regulating qi, regulating the middle, drying dampness, and resolving phlegm.

[0012] Spearmint, also known as green mint, is pungent, slightly warm, can relieve the symptoms, and regulate qi. The plant contains 0.6% to 0.7% of aromatic oil, which is called spearmint oil or green mint oil. The main component is celery oil mushroom ketone, which has a content of 60% to 65%. In addition, there are also active ingredients such as limonene and water celery oil. The main effects of spearmint are recorded in the "Chinese Medicine Dictionary" as: "It is mainly used to treat colds, coughs, headaches, sore throats, red eyes, epistaxis, stomachaches, abdominal distension, cholera vomiting and diarrhea, dysmenorrhea, limb numbness, swelling and pain from falls, sores, and chapped skin."

[0013] Asarum, also known as Xiaoxin and Duyecao, is pungent and warm, and enters the heart, lung, and kidney meridians. It has the effects of dispelling cold, dispelling wind and relieving pain, opening the orifices, warming the lungs and transforming fluid, and is often used for colds, headaches, toothaches, nasal congestion and runny nose, sinusitis, rheumatic pain, phlegm and cough.

[0014] The extract obtained by compounding the above-mentioned ingredients has a good effect on alleviating COPD disease.

[0015] The second aspect of the present invention is to provide a method for preparing the above-mentioned composition for alleviating chronic obstructive pulmonary disease, comprising the following steps: (1) Take 3-5 parts of patchouli leaves, 1-3 parts of lavender flowers, 1-3 parts of dried ripe citrus peels, 1-2 parts of spearmint stems and leaves, and 1-2 parts of asarum roots and stems, wash them separately and set aside; (2) The raw materials in (1) are crushed and squeezed in a juicer to obtain the squeezed oil of each raw material, and then dehydrated and separated from the squeezed residue of each raw material; (3) The squeezed residue of each raw material separated in (2) is distilled and condensed using water vapor for 3 to 4 hours, and the volatile components of each raw material are collected respectively, and the separated residues of each raw material after distillation are dried; (4) adding ethanol to the dried residues of the raw materials in (3) for extraction, and collecting the ethanol extracts of the raw materials; (5) The pressed oils of the raw materials obtained in (2), the volatile components of the raw materials obtained in (3), and the ethanol extracts of the raw materials obtained in (4) are combined, dried and dehydrated to obtain extracts of the raw materials, and the extracts of the raw materials are mixed uniformly to obtain the composition.

[0016] In the method for preparing the above-mentioned composition provided by the present invention, preferably, in (3), the water vapor temperature is 100° C. and the distillation time is 4 h.

[0017] Preferably, during the extraction in (4), the mass of ethanol added is 2 to 3 times the mass of the residue after drying, the extraction temperature is 40 to 50° C., and the extraction time is 0.5 to 2 h.

[0018] More preferably, during the extraction in (4), the mass of ethanol added is 2.5 times the mass of the residue after drying, the extraction temperature is 45°C, and the extraction time is 1 h.

[0019] Furthermore, the use of the above-mentioned composition in the preparation of an inhaled drug for relieving chronic obstructive pulmonary disease is also the technical content protected by the present invention.

[0020] Preferably, the drug is selected from any one of aerosol liquid, nasal spray, and nasal drops.

[0021] More preferably, the medicine is an aerosolized liquid.

[0022] As further preferred, the atomizing liquid at least includes an atomizing solvent and the above-mentioned composition, and the atomizing solvent is selected from at least one of glycerol and propylene glycol.

[0023] Preferably, in the atomized liquid, the composition is dissolved in the atomizing solvent at a mass percentage of 0.5% to 5%.

[0024] Furthermore, the method for using the atomized liquid is as follows: The nebulized liquid is atomized by electronic heating atomization, with a heating temperature of 200~220℃, a single heating time of 2~4 s, a cooling time of 27~57 s, and a cycle operation; each time the nebulization is started, it takes 30~60 minutes, 1~2 times a day, and is inhaled through the mouth and nose.

[0025] The beneficial effects of the present invention are: (1) Provided is a Chinese medicine preparation composition for relieving chronic obstructive pulmonary disease, which uses patchouli, lavender, citrus peel, spearmint and asarum as raw materials, and fully dissolves the active ingredients in each raw material by adopting a variety of different extraction methods. The active ingredients of each component in the obtained composition cooperate with each other to exert their effects, which not only has a good synergistic effect, but also has a low preparation and production cost and a high utilization rate; (2) In the present invention, the obtained composition is prepared into an aerosolized liquid and administered by inhalation through the mouth and nose. Experimental results show that the aerosolized liquid can significantly reduce mucus secretion, improve airway airflow obstruction, alleviate lung inflammation, improve lung function, and effectively alleviate chronic obstructive pulmonary disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 The effect of inhalation of aerosol liquid with different composition contents in Experimental Example 1 of the present invention on the content of inflammatory factors in the alveolar lavage fluid of mice; Figure 2 The lung function indicators FEV20 / FVC and FEV50 / FVC of mice after being treated with different contents of the composition in Experimental Example 2 of the present invention; Figure 3 The HE staining results of mouse lung tissue sections after inhalation of the aerosolized liquid of the composition at different contents in Experimental Example 3 of the present invention; Figure 4 The figures are the effects of treating mice with the compositions of different raw material ratios in Comparative Examples 1-8 of the present invention. DETAILED DESCRIPTION

[0027] In order to enable those skilled in the art to better understand the present invention, the present invention is further described in conjunction with specific implementation methods.

[0028] Example 1 A composition for relieving chronic obstructive pulmonary disease is prepared by the following method: (1) Take the following raw materials in parts by weight: 4 parts of patchouli leaves, 2 parts of lavender flowers, 2 parts of dried ripe citrus peels, 1 part of spearmint stems and leaves, and 1 part of asarum root and stem, wash them clean and set aside; (2) crushing the raw materials in (1) respectively and placing them in a juicer for squeezing to obtain the squeezed oil of each raw material, dehydrating the oil, and separating the squeezed residue of each raw material; (3) using 100°C steam to distill the pressing residues of the raw materials separated in (2) for 4 h, collecting the volatile components of each raw material respectively, and drying the residues of each raw material separated after distillation under reduced pressure at 55°C; (4) adding 2.5 times the mass of ethanol to the residue of each raw material after drying in (3), extracting at 45° C. for 1 h, and collecting the ethanol extract of each raw material; (5) The pressed oils of the raw materials obtained in (2), the volatile components of the raw materials obtained in (3) and the ethanol extracts of the raw materials obtained in (4) are combined and dried to obtain extracts of the raw materials. The extracts of the raw materials are mixed evenly to obtain the composition.

[0029] Example 2 The composition obtained in Example 1 was dissolved in glycerol at a mass percentage of 1.5% to form an atomized liquid.

[0030] The prepared atomized liquid was atomized by electronic heating atomization, with a heating temperature of 220 °C, a single heating time of 3 s, a cooling time of 57 s, and a cyclic operation.

[0031] Example 3 The difference from Example 2 is that the mass percentage of the composition in the atomized liquid is 0.5%.

[0032] Example 4 The difference from Example 2 is that the mass percentage of the composition in the atomized liquid is 5%.

[0033] Test Example 1 C57BL / 6J model mice were used to design different nebulized liquid inhalation doses (the composition accounted for 0.5% in the low-dose group, 1.5% in the medium-dose group, and 5% in the high-dose group), once a day, 1 hour each time, and divided into five groups, namely blank group (NOR), modeling group (CS), high-dose group (EO-H), medium-dose group (EO-M) and low-dose group (EO-L). After 80 days of inhalation, the inflammatory factors in the alveolar lavage fluid of each group of mice were investigated, and the results are shown in the attached figure. Figure 1 shown.

[0034] By the attached Figure 1 It can be seen that by measuring the inflammatory factors IL-1β, TNF-α, and IL-6 in the alveolar lavage fluid of mice, the results showed that compared with the blank group, the content of inflammatory factors in the alveolar lavage fluid of mice in the modeling group was significantly increased, and the content of inflammatory factors in the alveolar lavage fluid of mice was significantly decreased after treatment with high, medium, and low doses of the composition. It can be seen that the composition has a reducing effect on the increase of inflammatory factors in the lungs of mice and can alleviate COPD symptoms.

[0035] Test Example 2 C57BL / 6J model mice were used to design different nebulized liquid inhalation doses (the composition accounted for 0.5% in the low-dose group, 1.5% in the medium-dose group, and 5% in the high-dose group), once a day for 1 h each time, and divided into five groups, namely, blank group (NOR), modeling group (CS), high-dose group (EO-H), medium-dose group (EO-M) and low-dose group (EO-L). After 80 days of inhalation, the lung function indicators FEV20 / FVC (%) and FEV50 / FVC (%) of mice in each group were investigated. The measurement results are shown in the attached Figure 2 shown.

[0036] By the attached Figure 2 It can be seen that by measuring the lung function indicators FEV20 / FVC and FEV50 / FVC of mice, the results showed that the lung function of the mice in the modeling group was significantly reduced compared with the blank group, that is, the modeling was successful. The primary indicator for evaluating COPD disease, FEV20 / FVC, significantly improved lung function after treatment with the composition, and the treatment effect of the low-dose group was better than that of the high-dose group; FEV50 / FVC recovered lung function after treatment with the composition, which can indicate that the composition has a certain improvement effect on the lung function treatment of mice and can alleviate COPD symptoms.

[0037] Test Example 3 C57BL / 6J model mice were used to design different nebulized liquid inhalation doses (the proportion of the composition in the low-dose group was 0.5%, the proportion of the composition in the medium-dose group was 1.5%, and the proportion of the composition in the high-dose group was 5%), once a day, each time for 1 hour. A total of six groups were divided, namely, blank group, modeling group, blank solvent group (blank solvent refers to the nebulized liquid solvent, in order to prove that the solvent itself has no biological activity), high-dose group, medium-dose group and low-dose group. After 80 days of inhalation, the lung tissue pathological section staining of mice in each group was investigated. The results are shown in the attached figure. Figure 3 shown.

[0038] Attached Figure 3 The results of lung tissue pathological section staining showed that compared with the blank group, the alveolar cavity structure of the modeling group was disordered, the alveolar wall was significantly thickened, and there were a large number of inflammatory infiltrations; the characteristics of the solvent group were similar to those of the modeling group, proving that the solvent had no therapeutic effect on mice; after treatment with the composition, the area of ​​inflammatory infiltration was reduced to varying degrees, the alveolar wall became thinner, and the morphology of the alveolar cavity gradually recovered, and the treatment effect of the low-dose group was better than that of the high-dose group. It can be seen that the composition provided by the present invention has a significant improvement effect on alleviating chronic obstructive pulmonary disease.

[0039] On the basis of the above embodiments, the inventors also conducted the following experiments: Comparative Examples 1-8 are different from Example 1 in that the proportions of the components in the compositions of the comparative examples are different, as shown in Table 1 below.

[0040] Table 1 Ratios of the components in the compositions of Comparative Examples 1-8 Experimental Group Patchouli Lavender Citrus peel Spearmint Asarum Comparative Example 1 2 4 2 1 1 Comparative Example 2 1 4 1 2 2 Comparative Example 3 2 2 4 1 1 Comparative Example 4 1 1 4 2 2 Comparative Example 5 2 2 1 4 1 Comparative Example 6 1 1 2 4 2 Comparative Example 7 2 2 1 1 4 Comparative Example 8 1 1 2 2 4

[0041] After the above-mentioned comparative examples were used for treatment, the experimental results are shown in the attached Figure 4 As shown, there was no significant difference in the lung function index FEV20 / FVC of mice compared with the modeling group.

[0042] Comparative Example 9 The difference from Example 1 is that only the preparation process of the composition is adjusted, and the specific operations are as follows: The patchouli leaves, lavender flowers, dried and mature citrus peels, spearmint stems and leaves, and asarum roots and stems are taken in a formulated amount, crushed respectively, and then placed in a juicer for pressing to obtain pressed oils of the raw materials, which are then dehydrated to obtain extracts.

[0043] Comparative Example 10 The difference from Example 1 is that only the preparation process of the composition is adjusted, and the specific operations are as follows: Taking the patchouli leaves, lavender flowers, dried and mature citrus peels, spearmint stems and leaves, and asarum roots and stems in the prescribed amount, crushing them respectively and squeezing them in a juicer to obtain the squeezed oil of each raw material, and then dehydrating them; At the same time, the separated raw material pressing residue was treated with steam distillation and condensation for 4 hours to collect the volatile components; the pressed oil and the volatile components were combined and dried to obtain the extract.

[0044] The experimental results show that the extraction effect of the method of comparative examples 9-10 is poor, it is difficult to obtain the complete active ingredients in each component, and the purity of the obtained extract is not high, and the effect is poor.

Claims

1. A composition for relieving chronic obstructive pulmonary disease, characterized in that: The composition is prepared from the following raw materials in parts by weight: 3-5 parts of patchouli, 1-3 parts of lavender, 1-3 parts of citrus peel, 1-2 parts of spearmint, and 1-2 parts of asarum.

2. A composition for alleviating chronic obstructive pulmonary disease according to claim 1, characterized in that: The patchouli is patchouli leaves, the lavender is lavender flowers, the citrus peel is the dried ripe citrus peel, the spearmint is the stems and leaves of spearmint, and the asarum is the roots and stems of asarum.

3. A method for preparing a composition for alleviating chronic obstructive pulmonary disease according to claim 1, characterized in that: The steps include: (1) Take 3-5 parts of patchouli leaves, 1-3 parts of lavender flowers, 1-3 parts of dried ripe citrus peels, 1-2 parts of spearmint stems and leaves, and 1-2 parts of asarum roots and stems, wash them separately and set aside; (2) crushing the raw materials in (1) respectively and placing them in a juicer for squeezing to obtain the squeezed oil of each raw material, dehydrating the oil, and separating the squeezed residue of each raw material; (3) using water vapor to distill and condense the pressing residues of the raw materials separated in (2), the distillation time is 3 to 4 hours, collecting the volatile components of each raw material respectively, and drying the residues of each raw material separated after distillation; (4) adding ethanol to the dried residues of the raw materials in (3) for extraction, and collecting the ethanol extracts of the raw materials; (5) The pressed oils of the raw materials obtained in (2), the volatile components of the raw materials obtained in (3), and the ethanol extracts of the raw materials obtained in (4) are combined, dried and dehydrated to obtain extracts of the raw materials, and the extracts of the raw materials are mixed uniformly to obtain the composition.

4. The preparation method according to claim 3, characterized in that: (4), during extraction, the mass of ethanol added is 2 to 3 times the mass of the residue after drying, the extraction temperature is 40 to 50 °C, and the extraction time is 0.5 to 2 h.

5. Use of the composition according to claim 1 in the preparation of an inhaled drug for relieving chronic obstructive pulmonary disease.

6. The use according to claim 5, characterized in that The medicine is selected from any one of aerosol liquid, nasal spray and nasal drops.

7. The use according to claim 6, characterized in that The medicine is an aerosolized liquid.

8. The use according to claim 7, characterized in that The atomizing liquid at least comprises an atomizing solvent and the composition according to claim 1, and the atomizing solvent is selected from at least one of glycerol and propylene glycol.

9. The use according to claim 8, characterized in that In the atomized liquid, the composition is dissolved in the atomizing solvent at a mass percentage of 0.5% to 5%.

10. The use according to claim 7, characterized in that The method of using the atomized liquid is as follows: The nebulized liquid is atomized by electronic heating atomization, with a heating temperature of 200~220℃, a single heating time of 2~4 s, a cooling time of 27~57 s, and a cycle operation; each time the nebulization is started, it takes 30~60 minutes, 1~2 times a day, and is inhaled through the mouth and nose.

Images